Pharmaceutical heavyweight Novo Nordisk on Tuesday announced it is cutting prices for several insulin drugs in the U.S., following a similar move from drugmaker Eli Lilly as healthcare companies come under increasing pressure to lower prices for the lifesaving diabetes medication.
